Zydus Lifesciences gets USFDA nod to produce prostrate cancer …
WEB1 day ago — Zydus Lifesciences: The company has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide tablets (40 mg and 80 mg), the drug maker said in a regulatory filing. Enzalutamide tablets are androgen receptor inhibitors indicated for the treatment of patients with castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
Zydus Life shares in focus today after US FDA approves cancer …
WEB4 days ago — Zydus Life share price has jumped 76 percent over the past year, taking the company’s market capitalisation to over Rs 1.1 lakh crore. Zydus Lifesciences Ltd's shares gained as much as 1 percent ...
Zydus Lifesciences receives USFDA approval to produce prostrate …
WEB1 day ago — Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate cancer treatment drug. The company has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide tablets (40 mg and 80 mg), the drug maker said in a …
Zydus receives USFDA approval for ZITUVIO™ to treat adult …
WEBOct 20, 2023 — ZITUVIO™ contains active ingredient Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes...
WEBZITUVIOTM has undergone quality testing for Nitrosamines and potential genotoxic impurities as per current USFDA standards. ZITUVIOTM is compliant with current USFDA standards of Nitrosamines in Sitagliptin containing products.
Zydus aims to launch first new drug in US by early 2026
WEBFeb 27 (Reuters) - India's Zydus Lifesciences (ZYDU.NS) is aiming to launch its first new drug in the United States by early 2026, looking to tap into the multi-billion dollar market for treating...
Zydus receives USFDA approval for ZITUVIO™ to treat adult …
WEBOct 20, 2023 — ZITUVIO™ has undergone quality testing for Nitrosamines and potential genotoxic impurities as per current USFDA standards. ZITUVIO™ is compliant with current USFDA standards of Nitrosamines in...
Zydus appoints Mr. Punit Patel as President and CEO to lead its ...
WEBAHMEDABAD, India, Oct. 16, 2023 /PRNewswire/ -- Zydus Lifesciences Limited (including its subsidiaries/affiliates hereafter referred to as ' Zydus ') a discovery-driven, global lifesciences...
Zydus Group Latest Update, News And Press Releases - Zydus Life
WEBGet all the latest Zydus Group information, News, Videos, Press Releases and updates here.
India's Zydus Lifesciences Q1 profit beats estimates on strong US ...
WEBAug 9, 2024 — Indian drugmaker Zydus Lifesciences reported a bigger-than-expected first-quarter profit on Friday, driven by strong demand for its generic respiratory drugs in its key market of North America.